Consolidated Balance Sheets (Unaudited) - USD ($)	Jul. 31, 2025	Oct. 31, 2024
ASSETS
Cash	$ 175,081	$ 571,360
Inventory	174,072	115,365
Prepaid Expense	70,955	82,736
Total Current Assets	645,413	975,753
Goodwill	3,171,581	3,171,581
Intangible Assets, Net	335,227	358,084
Property and Equipment, Net	57,329	139,552
Patents, Net	155,067	89,548
Right of Use Asset – Operating Lease	255,658	346,091
Other Assets	8,438	8,438
Total Assets	4,628,713	5,089,047
LIABILITIES
Deferred Revenue, Net	525,387	525,387
Accrued Liabilities	1,863,630	1,806,419
2021 Series Convertible Note Payable – Related Party		480,000
Accrued Interest Payable – Related Party	450,914	81,679
2024 Series Senior Secured Convertible Notes Payable – Stock Settled, Net	593,750	4,718,750
2025 Series Senior Secured Convertible Notes Payable – Stock Settled, Net	1,684,876
Derivative/Warrant Liability	5,154,391	154,966
Unsecured 4% Note Payable – Related Party	1,221,958
Unsecured 6% Note Payable – Related Party	767,288
Current Maturities of Capital Lease Obligations	7,704	12,081
Current Maturities of Operating Lease Obligations	111,955	119,486
Total Current Liabilities	14,927,015	10,062,688
Capital Lease Obligations, Net of Current Portion		5,042
Operating Lease Obligation, Net of Current Portion	143,703	226,605
Unsecured 6% Note Payable – Related Party		767,288
Unsecured 4% Note Payable – Related Party		1,221,958
2022 Series Convertible Notes Payable	200,000	200,000
2023 Series Convertible Notes Payable - Stock Settled, Net	363,454	353,114
2023 Series B Convertible Notes Payable – Stock Settled, Net	598,711	507,273
Derivative/Warrant Liability	124,375	126,006
Long Term Accrued Interest Payable	350,376	240,123
Long Term Accrued Interest Payable – Related Party		379,923
Total Long-Term Liabilities	1,780,619	4,027,332
Total Liabilities	16,707,634	14,090,020
STOCKHOLDERS’ (DEFICIT)
Preferred Stock, 5,000,000 Shares Authorized, par value $0.001; Series A Convertible Preferred Stock, 250,000 Shares Authorized, 0 and 0 Outstanding, respectively; Series A-1 Convertible Preferred Stock, 750,000 Shares Authorized, 20,000 and 0 Outstanding, respectively	20
Common stock, 19,230,770 Shares Authorized, par value $0.001, 4,460,535 and 4,460,535 Outstanding, respectively	4,460	4,460
Additional Paid in Capital	31,962,278	29,028,260
Less Treasury Stock	(84,000)	(84,000)
Accumulated Deficit	(43,961,679)	(37,949,693)
Total Stockholders’ (Deficit)	(12,078,921)	(9,000,973)
Total Liabilities and Stockholders’ (Deficit)	4,628,713	5,089,047
Nonrelated Party [Member]
ASSETS
Accounts Receivable	209,555	206,292
LIABILITIES
Accounts Payable – Related Party	2,522,552	2,163,920
Related Party [Member]
ASSETS
Accounts Receivable	15,750
LIABILITIES
Accounts Payable – Related Party	$ 22,610

Vitro Biopharma, Inc. 10-Q